Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
09 December 2021Website:
http://www.neurosense-tx.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 04 Oct 2024 23:41:55 GMTDividend
Analysts recommendations
Institutional Ownership
NRSN Latest News
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the company's most pivotal event since its IPO at the end of 2021. The company is also targeting Alzheimer's and Parkinson's with the same drug candidate under different names.
What type of business is NeuroSense Therapeutics?
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
What sector is NeuroSense Therapeutics in?
NeuroSense Therapeutics is in the Healthcare sector
What industry is NeuroSense Therapeutics in?
NeuroSense Therapeutics is in the Biotechnology industry
What country is NeuroSense Therapeutics from?
NeuroSense Therapeutics is headquartered in Israel
When did NeuroSense Therapeutics go public?
NeuroSense Therapeutics initial public offering (IPO) was on 09 December 2021
What is NeuroSense Therapeutics website?
https://www.neurosense-tx.com
Is NeuroSense Therapeutics in the S&P 500?
No, NeuroSense Therapeutics is not included in the S&P 500 index
Is NeuroSense Therapeutics in the NASDAQ 100?
No, NeuroSense Therapeutics is not included in the NASDAQ 100 index
Is NeuroSense Therapeutics in the Dow Jones?
No, NeuroSense Therapeutics is not included in the Dow Jones index
When was NeuroSense Therapeutics the previous earnings report?
No data
When does NeuroSense Therapeutics earnings report?
Next earnings report date is not announced yet